ClinicalTrials.gg
CompletedNCT02453555Updated Feb 15, 2019Results posted

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Linagliptin and Empagliflozin placebo + linagliptin placebo low dose in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 40 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.

Enrollment
52nd of 96
275 · median 302
Started
2015
with 6 others
Phase 3
50 of 130
2 open now
Registered
93rd of 130
by date

Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 52nd largest by enrollment of the 96 interventional ones that give a count, is one of 7 that started in 2015, is one of 50 in phase 3, and was the 93rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Type-2 Diabetes Mellitus (T2DM) prior to
  2. Male and female patients on diet and exercise regimen for at least 12 weeks prior to informed consent who are:

    • 1 drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent, or
    • 2 pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of the maximum approved dose) on stable dosage for at least 12 weeks prior to informed consent (for thiazolidinedione, therapy has to be unchanged for at least 18 weeks prior to the informed consent, for linagliptin 5 mg at least 16 weeks prior to Visit 1). Individual antidiabetic drug (except linagliptin) will have to be discontinued at Visit 1.
  3. at Visit 1

    • 1 HbA1c =8.0% and =10.5% for patients who are drug-naïve, or
    • 2 HbA1c =7.5% and =10.5% for patients with one oral antidiabetic drug (except linagliptin), or
    • 3 HbA1c =7.5% and =10.0% for patients with linagliptin 5 mg
  4. HbA1c =7.5% and =10.0% at Visit 4 for randomisation into the double-blind treatment period. Patient who are pre-treated with linagliptin 5 mg for 16 weeks or more prior to Visit 1 and meet the criteria of HbA1c can directly move on to the run-in (Visit 4).
  5. Age =20 years at informed consent
  6. =40.0 kg/m2 at Visit 1 (screening)
  7. Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  1. Uncontrolled hyperglycemia with a glucose level >270 mg/dL (>15.0 mmol/L) after an overnight fast during the open-label stabilisation period (from Visit 2 to Visit 4) and run-in period (from Visit 4 to Visit 5) , confirmed by a second measurement (not on the same day and done either at the central or at local laboratory).
  2. Acute coronary syndrome (ST-elevation myocardial infarction [STEMI], non-STEMI, and unstable angina pectoris), stroke or within 12 weeks prior to
  3. Indication of liver disease, defined by serum levels of either (ALT Serum glutamic pyruvate transaminase [SGPT]), aspartate aminotransferase (AST, Serum glutamic oxaloacetic transaminase [SGOT]), or alkaline phosphatase (ALP) above 3 x (ULN) as determined during screening, open-label stabilisation period and/or run-in period
  4. Impaired renal function, defined as estimated (eGFR) \<45 mL/min/1.73 m2 (MDRD formula) as determined during screening, open-label stabilisation period and/or run-in period
  5. Known hereditary galactose intolerance
  6. Known to linagliptin and empagliflozin according to the Japanese label
  7. Any previous (within 2 years prior to informed consent) or planned bariatric surgery (or any other weight loss surgery) or other gastrointestinal surgery that induce chronic malabsorption
  8. Medical history of cancer (except for resected non-invasive basal cell or squamous carcinoma) and/or treatment for cancer within the last 5 years
  9. Known blood dyscrasias or any disorders causing haemolysis or unstable red blood cell (RBC) count (e.g. malaria, babesiosis, haemolytic anaemia).
  10. Treatment with insulin, Glucagon-like peptide-1 agonists, within 12 weeks prior to informed consent
  11. Treatment with anti-obesity drugs within 12 weeks prior to informed consent or any other treatment at the time of screening (i.e., surgery, aggressive diet regimen, etc.) leading to unstable body weight
  12. Current treatment with systemic (other than inhaled or topical steroids) at informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM
  13. Pre-menopausal women (last menstruation =1 year prior to informed consent) who:

    • 1 are nursing or pregnant or
    • 2 are of and are not practicing an acceptable method of , or do not plan to continue using this method throughout the trial and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, intra uterine devices/systems, oral contraceptives, complete sexual abstinence, double barrier method and vasectomised partner
  14. Known or suspected allergy or to trial products or related products (e.g., Dipeptidyl-peptidase-4 inhibitors or Sodium-glucose co-transporter-2 inhibitors)
  15. Alcohol or drug abuse within the 12 weeks prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to trial procedures or trial drug intake, by the judgment of the investigator
  16. Intake of an drug in another trial within 30 days prior to Visit 1 or participation in the follow-up period of another trial (participation in observational studies is permitted)
  17. Any other clinical condition that, in the opinion of the investigator, would jeopardize patient's safety while participating in this clinical trial
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
275 participants (actual)

Study arms

  • Active comparator
    Linagliptin

    patient to receive 5 mg linagliptin once daily

    Drug: Linagliptin · Drug: Empagliflozin placebo + linagliptin placebo low dose · Drug: Empa + lina highdose placebo

  • Experimental
    Empagliflozin + linagliptin low dose

    patient to receive one tablet once daily

    Drug: Empagliflozin + linagliptin low dose · Drug: Linagliptin placebo

  • Experimental
    Empagliflozin + linagliptin high dose

    patient to receive one tablet once daily

    Drug: Linagliptin placebo · Drug: Empagliflozin + linagliptin high dose

  • Placebo comparator
    Linagliptin placebo

    Drug: Empagliflozin + linagliptin low dose · Drug: Linagliptin placebo · Drug: Empagliflozin + linagliptin high dose

  • Placebo comparator
    Empagliflozin + linagliptin high dose placebo

    Drug: Linagliptin · Drug: Empa + lina highdose placebo

  • Placebo comparator
    Empagliflozin + linagliptin low dose placebo

    Drug: Linagliptin · Drug: Empagliflozin placebo + linagliptin placebo low dose

Interventions

  • Also known as: tablet

  • DrugEmpagliflozin placebo + linagliptin placebo low dose

    Matching placebo empagliflozin + linagliptin

  • DrugEmpagliflozin + linagliptin low dose

    tablet

  • DrugLinagliptin placebo

    Matching placebo linagliptin

  • DrugEmpagliflozin + linagliptin high dose

    tablet

  • DrugEmpa + lina highdose placebo
06

What researchers measure

Primary outcomes

  1. Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline)

    Change from baseline in Glycosylated haemoglobin A1c (HbA1c) at Week 24 was calculated as: HbA1c at Week 24 - HbA1c at baseline. Baseline is referred to the last observed measurement prior to the administration of randomized trial medication. Adjusted mean (Least square mean) and its standard error (SE) is presented.

    Time frame: Baseline and 24 week

Secondary outcomes

  1. Change in HbA1c From Week 28 at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Only)

    Change from Week 28 in HbA1c at Week 52 was calculated as: HbA1c at Week 52 - HbA1c at Week 28. Week 28 (pre up-titration) is referred to the last observed measurement prior to the first administration of any double-blind randomized trial medication in the up-titration period. Adjusted mean (Least square mean) and its standard error (SE) is presented. This endpoint was based on 1 group of the Full analysis set with up-titration (FASUT-II) whose dose was up-titrated to Empagliflozin 25 mg/Linagliptin 5 mg fixed dose combination thus there is no comparison group. Hence, no comparison is made. A restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach was used with baseline HbA1c as linear covariate and baseline eGFR, prior use of antidiabetic drug, visit as fixed effect(s). The covariance used to fit the model was unstructured.

    Time frame: 28 Week (pre up-titration) and 52 Week

  2. Change in HbA1c From Baseline at Week 52 (All Empagliflozin Versus All Placebo)

    Change from baseline in HbA1c at Week 52 was calculated as: HbA1c at Week 52 - HbA1c at baseline. Baseline is referred to the last observed measurement prior to the administration of randomized trial medication. Adjusted mean (Least square mean) and its standard error (SE) is presented.

    Time frame: Baseline and 52 week

  3. Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus Linagliptin 5 mg + Placebo 25 mg)

    Change from baseline in HbA1c at Week 52 was calculated as: HbA1c at Week 52 - HbA1c at baseline. Baseline is referred to the last observed measurement prior to the administration of randomized trial medication. Adjusted mean (Least square mean) and its standard error (SE) is presented.

    Time frame: Baseline and 52 week

  4. Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus All Placebo)

    Change from baseline in HbA1c at Week 52 was calculated as: HbA1c at Week 52 - HbA1c at baseline. Baseline is referred to the last observed measurement prior to the administration of randomized trial medication. Adjusted mean (Least square mean) and its standard error (SE) is presented.

    Time frame: Baseline and 52 week

07

Results

Posted Feb 15, 2019

Participant flow

24-week Double-blind Treatment Period
Participant flow — 24-week Double-blind Treatment Period
MilestoneEmpagliflozin 10 Milligram (mg)/Linagliptin 5 Milligram (mg)Linagliptin 5 mg + Placebo 10 mgEmpagliflozin 25 mg/Linagliptin 5 mg (Extension Period)Empagliflozin 10 mg/Linagliptin 5 mg (Extension Period)Linagliptin 5 mg + Placebo 25 mg (Extension Period)Linagliptin 5 mg + Placebo 10 mg (Extension Period)
Started182930000
Completed177860000
Not completed570000
Withdrew: Adverse event200000
Withdrew: Lost to follow-up100000
Withdrew: Withdrawal by subject240000
Withdrew: Other than specified above030000
Extension Period
Participant flow — Extension Period
MilestoneEmpagliflozin 10 Milligram (mg)/Linagliptin 5 Milligram (mg)Linagliptin 5 mg + Placebo 10 mgEmpagliflozin 25 mg/Linagliptin 5 mg (Extension Period)Empagliflozin 10 mg/Linagliptin 5 mg (Extension Period)Linagliptin 5 mg + Placebo 25 mg (Extension Period)Linagliptin 5 mg + Placebo 10 mg (Extension Period)
Started0012651806
Completed0012349795
Not completed003211
Withdrew: Adverse event001211
Withdrew: Protocol violation001000
Withdrew: Withdrawal by subject001000

Outcome measures

PrimaryChange of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline)

Change from baseline in Glycosylated haemoglobin A1c (HbA1c) at Week 24 was calculated as: HbA1c at Week 24 - HbA1c at baseline. Baseline is referred to the last observed measurement prior to the administration of randomized trial medication. Adjusted mean (Least square mean) and its standard error (SE) is presented.

Time frame:
Baseline and 24 week
Reported as:
Least squares mean · Percentage (%)
Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline)
Percentage (%)Empagliflozin 10 mg/Linagliptin 5 mgLinagliptin 5 mg + Placebo 10 mg
Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline)-0.93 ± 0.060.21 ± 0.09
Statistical analysis
  • Empagliflozin 10 mg/Linagliptin 5 mg vs Linagliptin 5 mg + Placebo 10 mg · Mixed Models Analysis · p = <0.0001 · Adjusted mean difference (net): -1.14 · 95% CI -1.36 to -0.91Adjusted Mean Difference was calculated as: (adjusted mean change from baseline in HbA1c at Week 24 in Empagliflozin 10 mg/linagliptin 5 mg group) - (adjusted mean change from baseline in HbA1c at Week 24 in Linagliptin 5 mg + Placebo 10 mg group)
SecondaryChange in HbA1c From Week 28 at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Only)

Change from Week 28 in HbA1c at Week 52 was calculated as: HbA1c at Week 52 - HbA1c at Week 28. Week 28 (pre up-titration) is referred to the last observed measurement prior to the first administration of any double-blind randomized trial medication in the up-titration period. Adjusted mean (Least square mean) and its standard error (SE) is presented. This endpoint was based on 1 group of the Full analysis set with up-titration (FASUT-II) whose dose was up-titrated to Empagliflozin 25 mg/Linagliptin 5 mg fixed dose combination thus there is no comparison group. Hence, no comparison is made. A restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach was used with baseline HbA1c as linear covariate and baseline eGFR, prior use of antidiabetic drug, visit as fixed effect(s). The covariance used to fit the model was unstructured.

Time frame:
28 Week (pre up-titration) and 52 Week
Reported as:
Least squares mean · Percentage (%)
Change in HbA1c From Week 28 at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Only)
Percentage (%)Empagliflozin 25 mg/Linagliptin 5 mg
Change in HbA1c From Week 28 at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Only)-0.21 ± 0.03
SecondaryChange in HbA1c From Baseline at Week 52 (All Empagliflozin Versus All Placebo)

Change from baseline in HbA1c at Week 52 was calculated as: HbA1c at Week 52 - HbA1c at baseline. Baseline is referred to the last observed measurement prior to the administration of randomized trial medication. Adjusted mean (Least square mean) and its standard error (SE) is presented.

Time frame:
Baseline and 52 week
Reported as:
Least squares mean · Percentage (%)
Change in HbA1c From Baseline at Week 52 (All Empagliflozin Versus All Placebo)
Percentage (%)All EmpagliflozinAll Placebo
Change in HbA1c From Baseline at Week 52 (All Empagliflozin Versus All Placebo)-1.16 ± 0.060.06 ± 0.10
Statistical analysis
  • All Empagliflozin vs All Placebo · Mixed Models Analysis · p = <0.0001 · Adjusted mean difference (net): -1.22 · 95% CI -1.45 to -0.99Adjusted Mean Difference was calculated as: (adjusted mean change from baseline in HbA1c at Week 52 in All Empagliflozin group) - (adjusted mean change from baseline in HbA1c at Week 52 in All Placebo group)
SecondaryChange in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus Linagliptin 5 mg + Placebo 25 mg)

Change from baseline in HbA1c at Week 52 was calculated as: HbA1c at Week 52 - HbA1c at baseline. Baseline is referred to the last observed measurement prior to the administration of randomized trial medication. Adjusted mean (Least square mean) and its standard error (SE) is presented.

Time frame:
Baseline and 52 week
Reported as:
Least squares mean · Percentage (%)
Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus Linagliptin 5 mg + Placebo 25 mg)
Percentage (%)Empagliflozin 25 mg/Linagliptin 5 mgLinagliptin 5 mg + Placebo 25 mg
Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus Linagliptin 5 mg + Placebo 25 mg)-1.10 ± 0.070.11 ± 0.10
Statistical analysis
  • Empagliflozin 25 mg/Linagliptin 5 mg vs Linagliptin 5 mg + Placebo 25 mg · Mixed Models Analysis · p = <0.0001 · Adjusted mean difference (net): -1.21 · 95% CI -1.45 to -0.96Adjusted Mean Difference was calculated as: (adjusted mean change from baseline in HbA1c at Week 52 in Empagliflozin 25 mg/linagliptin 5 mg group) - (adjusted mean change from baseline in HbA1c at Week 52 in Linagliptin 5 mg + Placebo 25 mg group)
SecondaryChange in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus All Placebo)

Change from baseline in HbA1c at Week 52 was calculated as: HbA1c at Week 52 - HbA1c at baseline. Baseline is referred to the last observed measurement prior to the administration of randomized trial medication. Adjusted mean (Least square mean) and its standard error (SE) is presented.

Time frame:
Baseline and 52 week
Reported as:
Least squares mean · Percentage (%)
Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus All Placebo)
Percentage (%)Empagliflozin 25 mg/Linagliptin 5 mgAll Placebo
Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus All Placebo)-1.10 ± 0.07-0.01 ± 0.10
Statistical analysis
  • Empagliflozin 25 mg/Linagliptin 5 mg vs All Placebo · Mixed Models Analysis · p = <0.0001 · Adjusted mean difference (net): -1.09 · 95% CI -1.34 to -0.84Adjusted Mean Difference was calculated as: (adjusted mean change from baseline in HbA1c at Week 52 in Empagliflozin 25 mg/linagliptin 5 mg group) - (adjusted mean change from baseline in HbA1c at Week 52 in All Placebo group)

Adverse events

Collected over From first drug administration till 52 weeks, up to 7 days after last drug administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Empagliflozin—8/182 (4.4%)62/182 (34.1%)
All Placebo—1/93 (1.1%)46/93 (49.5%)
Most frequent serious events
Most frequent serious events
EventAll EmpagliflozinAll Placebo
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/1821/93
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1820/93
Adrenal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1820/93
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1820/93
Cerebral haemorrhageNervous system disorders1/1820/93
GlaucomaEye disorders1/1820/93
Prinzmetal anginaCardiac disorders1/1820/93
CholelithiasisHepatobiliary disorders1/1820/93
Patella fractureInjury, poisoning and procedural complications1/1820/93
Foot fractureInjury, poisoning and procedural complications1/1820/93
Most frequent other events
Most frequent other events
EventAll EmpagliflozinAll Placebo
NasopharyngitisInfections and infestations35/18234/93
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders14/18210/93
Asymptomatic bacteriuriaInfections and infestations13/1826/93
Blood ketone body increasedInvestigations12/1821/93

Baseline characteristics

The full analysis set (FAS) consisted of all patients who were randomised and treated with at least 1 dose of trial drug and had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the 24 week double-blind part of the trial.

Age, Continuous
Age, Continuous(Years)Empagliflozin 10 mg/Linagliptin 5 mgLinagliptin 5 mg + Placebo 10 mgTotal
Mean60.0 ± 9.959.8 ± 10.859.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Empagliflozin 10 mg/Linagliptin 5 mgLinagliptin 5 mg + Placebo 10 mgTotal
Female402161
Male14272214
08

Study locations

40 sites
  • Nagoya Kyoritsu Hospital
    Aichi, Nagoya, 454-0933, Japan
  • Kashiwa City Hospital
    Chiba, Kashiwa, 277-0825, Japan
  • Otabe internal medicine clinic
    Fukuoka, Fukuoka, 811-1346, Japan
  • Nakamura Cardiovascular Clinic
    Fukuoka, Itoshima, 819-1104, Japan
  • Tanaka I.M. Clinic, Fukuoka, I.M.
    Fukuoka, Kurume, 830-0023, Japan
  • Seino I.M. Clinic, Fukushima, I.M.
    Fukushima, Koriyama, 963-8851, Japan
  • Hiraoka Naika Clinic, Hiroshima, I.M.
    Hiroshima, Hiroshima, 733-0011, Japan
  • Matsuda Cardiovascular Clinic
    Hokkaido, Sapporo, 003-0026, Japan
  • Teine Keijinkai Clinic
    Hokkaido, Sapporo, 006-0811, Japan
  • Mita Internal Medicine Cardiology Clinic
    Hokkaido, Sapporo, 006-0852, Japan
  • Miyanosawa Clinic of Internal Medicine and Cardiology
    Hokkaido, Sapporo, 063-0826, Japan
  • Itabashi Diabetic medicine and Dermatology Clinic
    Ibaraki, Koga, 306-0232, Japan
  • Nakakinen Clinic
    Ibaraki, Naka, 311-0113, Japan
  • Kubota Clinic
    Kanagawa, Kawasaki, 214-0014, Japan
  • Kitasato University Hospital
    Kanagawa, Sagamihara, 252-0375, Japan
  • H.E.C Science Clinic
    Kanagawa, Yokohama, 235-0045, Japan
  • Yoshimasa Diabetes & Endocrine Clinic
    Kyoto, Kyoto, 604-8151, Japan
  • Rakuwakai Otowa Hospital
    Kyoto, Kyoto, 607-8062, Japan
  • Medical Corporation Hayashi Katagihara Clinic
    Kyoto, Kyoto, 615-8125, Japan
  • Miyamoto Naika Clinic, Nagano, I.M.
    Nagano, Matsumoto, 390-0848, Japan
  • Gibo Hepatology Clinic, Nagano, Digestive Tract I.M.
    Nagano, Matsumoto, 399-0036, Japan
  • Takekawa Clinic, Osaka, I.M.
    Osaka, Higashi-Osaka, 577-0803, Japan
  • Medical Corporation Koseikai Fukuda Naika Clinic
    Osaka, Osaka, 532-0003, Japan
  • Kinugawa Cardiovascular Internal Medicine clinic
    Osaka, Osaka, 532-0026, Japan
  • Sato Hospital
    Osaka, Osaka, 536-0023, Japan
  • Nakaoka Clinic
    Osaka, Osaka, 555-0032, Japan
  • OCROM Clinic
    Osaka, Suita, 565-0853, Japan
  • Miyauchi Medical Center
    Osaka, Takatsuki, 569-1123, Japan
  • Medical Corporation Shinseikai Mashiba Clinic
    Saitama, Hanno, 357-0024, Japan
  • Asano Clinic
    Saitama, Kawagoe, 350-0851, Japan
  • Medical Corporation Fusa Shimizu Clinic Fusa
    Saitama, Saitama, 336-0963, Japan
  • Ogino Clinic
    Saitama, Tokorozawa, 359-1161, Japan
  • Kanda Clinic
    Tokyo, Chiyoda-ku, 101-0047, Japan
  • Fukuwa Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Tokyo-Eki Center-building Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Myojin Tou Clinic
    Tokyo, Hachioji, 192-0046, Japan
  • Sawai Medical Clinic
    Tokyo, Koto-ku, 136-0073, Japan
  • Mishuku Hospital
    Tokyo, Meguro-ku, 153-0051, Japan
  • Toshiba General Hospital
    Tokyo, Shinagawa-ku, 140-8522, Japan
  • ToCROM Clinic
    Tokyo, Shinjuku-ku, 160-0022, Japan
09

References and documents

Publications

  • Kawamori R, Haneda M, Suzaki K, Cheng G, Shiki K, Miyamoto Y, Solimando F, Lee C, Lee J, George J. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2018 Sep;20(9):2200-2209. doi: 10.1111/dom.13352. Epub 2018 Jun 1. PubMed 29766636 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Aug 2016, 15 months.

Results were first posted in Feb 2019, 2 years 5 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2015
First posted
May 25, 2015
StartActual
May 14, 2015
Primary completionActual
Aug 26, 2016
CompletionActual
Mar 27, 2017
Results first posted
Feb 15, 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02453555
Responsible party
Sponsor
First posted
May 25, 2015
Start date
May 14, 2015
Primary completion
Aug 26, 2016
Completion
Mar 27, 2017
Results posted
Feb 15, 2019
Last update
Feb 15, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion